Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
$6.74
-2.6%
$5.48
$3.79
$14.60
$337.69M-0.911.52 million shs711,469 shs
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$59.96
+6.8%
$34.15
$10.14
$61.60
$1.21B1.14213,412 shs1.11 million shs
CARGO Therapeutics, Inc. stock logo
CRGX
CARGO Therapeutics
$4.57
-0.4%
$4.33
$3.00
$25.45
$210.72M0.28735,885 shs1.74 million shs
Renovacor, Inc. stock logo
RCOR
Renovacor
$3.20
$3.07
$1.34
$9.74
$55.26M-0.2830,033 shsN/A
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-2.60%+16.01%+36.99%+47.48%+2.59%
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
+6.79%+18.66%+181.37%+208.44%+360.88%
CARGO Therapeutics, Inc. stock logo
CRGX
CARGO Therapeutics
-0.44%-0.44%+5.06%-1.51%-74.06%
Renovacor, Inc. stock logo
RCOR
Renovacor
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
2.5795 of 5 stars
3.61.00.00.03.41.70.6
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
3.6546 of 5 stars
2.62.00.04.63.71.70.0
CARGO Therapeutics, Inc. stock logo
CRGX
CARGO Therapeutics
2.3536 of 5 stars
2.90.00.00.02.71.71.3
Renovacor, Inc. stock logo
RCOR
Renovacor
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
3.20
Buy$22.00226.41% Upside
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
3.11
Buy$57.29-4.46% Downside
CARGO Therapeutics, Inc. stock logo
CRGX
CARGO Therapeutics
1.86
Reduce$15.40236.98% Upside
Renovacor, Inc. stock logo
RCOR
Renovacor
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest RCOR, CADL, CRGX, and CDTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$69.00
7/9/2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/8/2025
CARGO Therapeutics, Inc. stock logo
CRGX
CARGO Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$3.70 ➝ $5.00
6/30/2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$23.00
6/30/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$59.00
6/24/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
6/24/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Moderate Buy$35.00 ➝ $75.00
6/24/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$50.00 ➝ $68.00
6/23/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$41.00 ➝ $53.00
6/23/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$36.00 ➝ $54.00
6/23/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
WBB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingStrong-Buy ➝ Strong-Buy$45.00
(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
$120K2,813.95N/AN/A$1.41 per share4.78
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$1.27M951.81N/AN/A$14.92 per share4.02
CARGO Therapeutics, Inc. stock logo
CRGX
CARGO Therapeutics
N/AN/AN/AN/A$7.83 per shareN/A
Renovacor, Inc. stock logo
RCOR
Renovacor
N/AN/AN/AN/A$2.47 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-$55.18M-$1.34N/AN/AN/AN/A-136.74%-63.13%8/12/2025 (Estimated)
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$169.83M-$29.47N/AN/AN/AN/A-73.04%-54.28%8/12/2025 (Estimated)
CARGO Therapeutics, Inc. stock logo
CRGX
CARGO Therapeutics
-$167.50M-$4.62N/AN/AN/AN/A-45.93%-39.58%8/11/2025 (Estimated)
Renovacor, Inc. stock logo
RCOR
Renovacor
-$14.10M-$0.73N/AN/AN/AN/A-62.88%-48.90%N/A

Latest RCOR, CADL, CRGX, and CDTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-$0.17N/AN/AN/AN/AN/A
8/12/2025Q2 2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$1.87N/AN/AN/AN/AN/A
8/11/2025Q2 2025
CARGO Therapeutics, Inc. stock logo
CRGX
CARGO Therapeutics
-$0.42N/AN/AN/AN/AN/A
5/13/2025Q1 2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-$0.24$0.13+$0.37$0.13N/AN/A
5/8/2025Q1 2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$5.45-$1.66+$3.79-$1.66N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
N/AN/AN/AN/AN/A
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/AN/AN/AN/AN/A
CARGO Therapeutics, Inc. stock logo
CRGX
CARGO Therapeutics
N/AN/AN/AN/AN/A
Renovacor, Inc. stock logo
RCOR
Renovacor
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
0.01
4.64
4.64
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/A
3.87
3.87
CARGO Therapeutics, Inc. stock logo
CRGX
CARGO Therapeutics
N/A
6.30
6.30
Renovacor, Inc. stock logo
RCOR
Renovacor
N/A
6.60
6.60

Institutional Ownership

CompanyInstitutional Ownership
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
13.93%
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
35.82%
CARGO Therapeutics, Inc. stock logo
CRGX
CARGO Therapeutics
93.16%
Renovacor, Inc. stock logo
RCOR
Renovacor
45.84%

Insider Ownership

CompanyInsider Ownership
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
16.60%
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
3.89%
CARGO Therapeutics, Inc. stock logo
CRGX
CARGO Therapeutics
2.92%
Renovacor, Inc. stock logo
RCOR
Renovacor
14.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
6050.10 million41.79 millionOptionable
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
9020.16 million19.38 millionNo Data
CARGO Therapeutics, Inc. stock logo
CRGX
CARGO Therapeutics
11646.11 million44.76 millionN/A
Renovacor, Inc. stock logo
RCOR
Renovacor
1917.27 million14.78 millionNot Optionable

Recent News About These Companies

Renovacor, Inc. Common Stock (RCOR)
The Lititz Record-Express
WNBA Delivers Record-Setting 2024 Season
RBC Core Bond Pool ETF (RCOR)
News of Record
The best early Black Friday turntable deals 2023

New MarketBeat Followers Over Time

Media Sentiment Over Time

Candel Therapeutics stock logo

Candel Therapeutics NASDAQ:CADL

$6.74 -0.18 (-2.60%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$6.78 +0.04 (+0.52%)
As of 07/18/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Cidara Therapeutics stock logo

Cidara Therapeutics NASDAQ:CDTX

$59.96 +3.81 (+6.79%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$60.30 +0.34 (+0.57%)
As of 07/18/2025 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

CARGO Therapeutics stock logo

CARGO Therapeutics NASDAQ:CRGX

$4.57 -0.02 (-0.44%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$4.57 0.00 (0.00%)
As of 07/18/2025 05:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

Renovacor stock logo

Renovacor NYSE:RCOR

Renovacor, Inc., a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM). The company's lead product candidate is REN-001, a recombinant adeno-associated virus 9-based gene therapy designed to deliver a functional BAG3 gene to augment BAG3 protein levels in cardiomyocytes, and slow or halt progression of BAG3 DCM. It is also developing a pipeline of BAG3-associated gene therapies for diseases with high unmet medical need associated with mutations in the BAG3 gene and mechanistically linked to BAG3's expression and function. The company was founded in 2013 and is based in Greenwich, Connecticut.